Journal of Clinical Oncology · 1991 · 142 citations · 11 references
MedicineOncologyPediatricsChemotherapyPediatric NephrologyRenal PathophysiologyNephrotoxic Drug ManagementNephrotoxicity ManagementRenal DiseaseRenal ToxicityChemotherapy-associated NephrotoxicityIfosfamide NephrotoxicityMedication-related NephrotoxicityNephrotoxic InjuryNephrotoxic MedicationsNephrotoxic SyndromePlatinum-based Chemotherapy Renal ToxicityTotal Dose
Three of 218 children treated with ifosfamide plus the uroprotectant mesna, in single- or combination-agent protocols, have developed Fanconi's renal syndrome, all of whom were in a subgroup of 86 children who had also received cisplatin or carboplatin therapy. Patients receiving ifosfamide who have received prior cisplatin (or carboplatin) are at significantly higher risk of developing Fanconi's syndrome than are those who have received no prior nephrotoxic therapy (P = .04). The role of prior nephrotoxic therapy, including cisplatin and its derivatives, and the total dose of ifosfamide should be considered in the assessment of this rare but serious and apparently irreversible side effect.
11
Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor
Carol D. Burk, Irene Restaino, Bernard S. Kaplan et al. · The Journal of Pediatrics · 1990 · 106 citations
Medicine, Nephrology, Oncology +16
Hypophosphataemic rickets after ifosfamide treatment in children.
Roderick Skinner, Andrew D.J. Pearson, L Price et al. · BMJ · 1989 · 67 citations · Full text
Fanconi syndrome after ifosfamide
M W Moncrieff, A. B. M. Foot · Cancer Chemotherapy and Pharmacology · 1989 · 65 citations